Filter posts

Setting the Record Straight on Innovation and Drug Development

Modern biotechnology is a relatively young industry, but in just over 40 years, the entrepreneurs, …

Do Outcomes Matter When There Is Chronic Misalignment?

This piece by Allan L. Shaw was originally published in Life Science Leader. With over …

See What’s New at the 2015 BIO Investor Forum

The 2015 BIO Investor Forum is just two weeks away, and it’s gearing up to …

Biomarkets: Looking For The Hole In The Donut

This piece by Allan L. Shaw was originally published in Life Science Leader. The biopharma …

Politicking Biopharma Delays Cures

Forbes’ Matthew Herper ran a guest post from Robert Nelsen, cofounder and managing director of …

Warning: Don’t Let Bio-Euphoria Distract You from Being Disciplined

This piece by Allan L. Shaw was originally published in Life Science Leader. We currently …

Discover Trends and Investment Opportunities at the BIO Investor Forum

The 2015 BIO Investor Forum in San Francisco is shaping up to be a must-attend event …

The Investment Landscape in Brazil

Brazil has been at the forefront of biotech news recently, with China announcing plans to …

Academics Weigh In on Journal Article: “GMOs, Herbicides, and Public Health”

An article published in the New England Journal of Medicine by biotech critics Philip Landrigan …

Joint U.S.-Brazil Communique Demonstrates Commitment to Collaboration

In June, Brazilian President Dilma Rousseff met with President Barack Obama to reaffirm their commitment …